Carson brings with him over two decades of experience in Communications, Public Affairs, and Sustainability
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Strong topline growth driven by solid performance across key brands.
This tie-up will have no impact on any other brands of the company
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
General Medicine grows 5% and Vaccines 10% led by Shingrix
The company has reported total income of Rs. 815.11 crores during the period ended March 31, 2023
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
